Building our own community for an ultra-rare diseaseBo Bigelow shares the story of his daughter Tess, who has an ultra-rare genetic disorder with only 51 Share XBuilding our own community for an ultra-rare diseasehttps://pharmaphorum.com/views-and-analysis/building-our-own-community-for-an-ultra-rare-disease/
The Falsified Medicines Directive – truly an opportunity for pharma?Telling the fake from the true is often a challenge, particularly in this era of ‘fake news’. But, Share XThe Falsified Medicines Directive – truly an opportunity for pharma?https://pharmaphorum.com/spotlight/future-of-generics/falsified-medicines-directive-opportunity-pharma/
Spotlight on the future of genericsGeneric drugs play a vital role in ensuring affordable access to healthcare and the future sustainability of medicines Share XSpotlight on the future of genericshttps://pharmaphorum.com/views-and-analysis/spotlight-future-generics-accord-healthcare/
ASCO 2019 round-upWith the American Society of Clinical Oncology (ASCO) conference over for another year, Richard Staines presents a round-up Share XASCO 2019 round-uphttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-round-up/
ASCO 2019 – Kantar takes a first look at interim data from the Phase 3 TITAN trialWill Erleada take the lead in metastatic CSPC? New interim data at ASCO 2019 from the Phase 3 Share XASCO 2019 – Kantar takes a first look at interim data from the Phase 3 TITAN trialhttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-kantar-interim-data-phase-3-titan-trial/
ASCO 2019 Preview – in partnership with KantarASCO’s 2019 conference is due to begin in just a few days’ time, highlighting the latest cutting edge Share XASCO 2019 Preview – in partnership with Kantarhttps://pharmaphorum.com/views-analysis-oncology/asco-2019-preview-partnership-kantar/
ASCO 2019 and the future of oncologyThe future of oncology is to be showcased at ASCO 2019 when the world’s leading cancer event returns Share XASCO 2019 and the future of oncologyhttps://pharmaphorum.com/views-and-analysis/spotlight-asco-2019-future-oncology/
Spotlight on behavioural science in pharmaBehavioural science, and the changes it can bring to patient and healthcare provider behaviour, has important implications for Share XSpotlight on behavioural science in pharmahttps://pharmaphorum.com/views-and-analysis/spotlight-behavioural-science-pharma/
A spotlight on patient-provider dialoguePatient-provider communication impacts both short- and long-term outcomes. Research demonstrates that poor communication leads to distress, uncertainty, internal Share XA spotlight on patient-provider dialoguehttps://pharmaphorum.com/views-and-analysis/behavioural-science-patient-provider-dialogue/
